TipRanks
CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1
Germany Market

CytomX Therapeutics (6C1) Drug Pipeline

6 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Pembrolizumab, Keytruda, Cx-801
Solid Tumor, Adult
Phase I
Recruiting
First In Human Study of CX-801 in Advanced Solid Tumors
Jun 12, 2024
―
Cx-2051
Solid Tumor, Adult
Phase I
Recruiting
First In Human Study of CX-2051 in Advanced Solid Tumors
Feb 12, 2024
Cx-904
Solid Tumors
Phase I
Terminated
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
May 19, 2022
―
Ipilimumab, Cx-072
Solid Tumor, Unresectable Or Metastatic Melanoma
Phase II
Terminated
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
May 14, 2019
―
Ipilimumab, Vemurafenib, Cx-072
Solid Tumor, Lymphoma
Phase I/II
Terminated
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Dec 26, 2016
―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does CytomX Therapeutics Inc (6C1) have in its pipeline
      6C1 is currently developing the following drugs: Pembrolizumab, Keytruda, Cx-801, Cx-2051, Cx-904. These drug candidates are in various stages of clinical development as the company works toward FDA approval.